Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle

Executive Summary

Roche gave updates on its immunotherapy research at ASCO, setting the stage for an ambitious slate of combination trials with the company's PD-L1 inhibitor atezolizumab.

Advertisement

Related Content

Roche Pushes The Boundaries Of Cancer Immunotherapy
Roche’s Immuno-Oncology Arsenal: PD-L1 And Beyond
Roche's Oncology Strategy: The Long Game Comes Into Focus

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel